The American Journal of Medicine
Volume 111, Issue 8 , Pages 607-613 , 1 December 2001

Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome

  • Richard S Legro, MD

      Affiliations

    • Department of Obstetrics and Gynecology (RSL), Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
    • ,
  • Allen R Kunselman, MA

      Affiliations

    • Department of Health Evaluation Sciences (ARK), Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
    • ,
  • Andrea Dunaif, MD

      Affiliations

    • Corresponding Author InformationRequest for reprints should be addressed to Andrea Dunaif, MD, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Medical School, 303 East Chicago Avenue, Tarry 15-709, Chicago, Illinois 60611-3008 USA
    • Division of Women’s Health (AD), Departments of Medicine and Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, Massachusetts, USA

Received 15 November 2000 ,Accepted 31 July 2001.

References 

  1. Wild RA, Painter PC, Coulson PB, et al.  Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985;61:946–951
  2. Graf MJ, Richards CJ, Brown V, et al.  The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women. Clin Endocrinol. 1990;33:119–131
  3. Talbott E, Guzick D, Clerici A, et al.  Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscl Thromb Vasc Biol. 1995;15:821–826
  4. Rajkhowa M, Neary RH, Kumpatla P, et al.  Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:3389–3394
  5. Reaven GM. Banting Lecture 1988 (Role of insulin resistance in human disease). Diabetes. 1988;37:1595–1607
  6. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol. 1992;37:119–125
  7. Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome (relation to anthropometric, endocrine and metabolic variables). Clin Endocrinol. 1994;41:463–471
  8. Robinson S, Henderson AD, Gelding SV, et al.  Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol. 1996;44:277–284
  9. von Eckardstein S, von Eckardstein A, Bender HG, et al.  Elevated low-density lipoprotein-cholesterol in women with polycystic ovary syndrome. Gynecol Endocrinol. 1996;10:311–318
  10. Talbott E, Clerici A, Berga SL, et al.  Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome (results of a case-control study). J Clin Epidemiol. 1998;51:415–422
  11. Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril. 2000;73:150–156
  12. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries—a common finding in normal women. Lancet. 1988;1:870–872
  13. Freedman DS, Lee SL, Byers T, et al.  Serum cholesterol levels in a multiracial sample of 7,439 preschool children from Arizona. Prev Med. 1992;21:162–176
  14. Legro RS, Blanche P, Krauss RM, Lobo RA. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome (influence of insulin and genetic factors). Fertil Steril. 1999;72:990–995
  15. Ovesen P, Moller J, Ingerslev HJ, et al.  Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1993;77:1636–1640
  16. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome (a prospective, controlled study in 254 affected women). J Clin Endocrinol Metab. 1999;84:165–169
  17. DeFronzo RA, Ferrannini E. Insulin resistance (A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease). Diabetes Care. 1991;14:173–194
  18. Mitchell BD, Stern MP, Haffner SM, et al.  Risk factors for cardiovascular mortality in Mexican Americans and non-Hispanic Whites. San Antonio Heart Study. Am J Epidemiol. 1990;131:423–433
  19. Dunaif A, Scott D, Finegood D, et al.  The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81:3299–3306
  20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  21. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Women . Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA. 1993;269:3015–3023
  22. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694–2698
  23. Clevidence BA, Reichman ME, Judd JT, et al.  Effects of alcohol consumption on lipoproteins of premenopausal women. A controlled diet study. Arterioscl Thromb Vasc Biol. 1995;15:179–184
  24. Wei M, Mitchell BD, Haffner SM, Stern MP. Effects of cigarette smoking, diabetes, high cholesterol, and hypertension on all-cause mortality and cardiovascular disease mortality in Mexican Americans (The San Antonio Heart Study). Am J Epidemiol. 1996;144:1058–1065
  25. Turley ML, Skeaff CM, Mann JI, Cox B. The effect of a low-fat high-carbohydrate diet on serum high density lipoprotein cholesterol and triglyceride. Eur J Clin Nutr. 1998;52:728–732
  26. Slowinska-Srzednicka J, Zgliczynski S, Wierzbicki M, et al.  The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. J Endocrinol Invest. 1991;14:569–575
  27. Sempos CT, Cleeman JI, Carroll MD, et al.  Prevalence of high blood cholesterol among U.S. adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA. 1993;269:3009–3014
  28. Edman CD, MacDonald PC. Effect of obesity on conversion of plasma androstenedione to estrone in ovulatory and anovulatory young women. Am J Obstet Gynecol. 1978;130:456–461
  29. Nestler JE, Powers LP, Matt DW, et al.  A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72:83–89
  30. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality (The Framingham Heart Study). Arteriosclerosis. 1988;8:737–741
  31. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993;153:2209–2216
  32. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  33. Pierpoint T, McKeigue PM, Isaacs AJ, et al.  Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol. 1998;51:581–586
  34. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al.  Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscl Thromb Vasc Biol. 2000;20:2414–2421

☆ Supported by Grants DK 40605, HD 0118, HD 34449, RR 10732, and RR 02635 from the National Institutes of Health.

PII: S0002-9343(01)00948-2

The American Journal of Medicine
Volume 111, Issue 8 , Pages 607-613 , 1 December 2001

Article Tools